Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387911 | 0.83 | MEN1 (0.48) | KDM4EGABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL830378 | 0.82 | ALDH1A1 (0.71) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL29236560 | 0.81 | GABRA1 (0.51) | KDM4EALDH1A1MAPTGAARAB9A | |
| SCHEMBL12597633 | 0.79 | ALDH1A1 (0.61) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL832372 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL14602590 | 0.71 | ALDH1A1 (0.63) | KDM4EALDH1A1MAPTGABRA1GABRG2 | |
| SCHEMBL27385781 | 0.71 | GABRA1 (0.44) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL23901082 | 0.70 | MAP2K4 (0.47) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL2351650 | 0.70 | GABRA1 (0.60) | KDM4EALDH1A1MAPTGAANPC1 | |
| SCHEMBL832227 | 0.70 | RAB9A (0.67) | KDM4EALDH1A1NPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | KDM4E 2071/4885ALDH1A1 2482/4885MAPT 424/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | KDM4E 1061/4885ALDH1A1 1792/4885MAPT 1047/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | KDM4E 1111/4885ALDH1A1 800/4885MAPT 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.